These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35614270)

  • 1. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
    Helminen O; Melkko J; Saarnio J; Sihvo E; Kuopio T; Ohtonen P; Kauppila JH; Karttunen TJ; Huhta H
    Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
    Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
    Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
    Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
    J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
    Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
    Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.
    Helminen O; Huhta H; Leppänen J; Kauppila JH; Takala H; Lehenkari PP; Saarnio J; Karttunen TJ
    Virchows Arch; 2016 Oct; 469(4):465-70. PubMed ID: 27392931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
    Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
    Younes M; Lebovitz RM; Lechago LV; Lechago J
    Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
    Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
    Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
    Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
    Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
    Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma.
    Rice TW; Goldblum JR; Falk GW; Tubbs RR; Kirby TJ; Casey G
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1132-7. PubMed ID: 7983883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
    Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
    Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.